Guanidinobenzoatase is a trypsin-like protease associated with tumour cells (Steven et al., 1985) which may be assayed in solution by the cleavage of methylumbelliferone from the fluorogenic substrate 4-methylumbelliferyl-p-guanidinobenzoate (Steven & Al-Ahmad, 1983 ). This protease has been shown to cleave the tetrapeptide GlyArgGlyAsp which is thought to link cell surfaces to fibronectin (Pierschbacher & Ruoslahti, 1984) . Guanidinobenzoatase is competitively inhibited by 9-aminoacridine (Steven et al., 1985) , and this observation was used to locate tumour cells containing guanidinobenzoatase by fluorescent microscopy of formaldehyde fixed wax embedded sections. It was later established that most host tissues contained extractable proteins which were non-competitive inhibitors of guanidinobenzoatase in solution (Steven et al., 1988a) . These protein inhibitors prevented the binding of 9-aminoacridine to the protease of most tumour cells in fresh frozen sections (Steven et al., 1988b) , whilst some tumour cells possessed uninhibited enzyme in these frozen sections. In the present paper we have studied those tumour cells in frozen sections which possess uninhibited guanidinobenzoatase. When treated with 9-aminoacridine and examined by fluorescent microscopy these uninhibited cells exhibit cytoplasmic and cell surface yellow fluorescence; whilst other morphologically similar tumour cells with fully inhibited guanidinobenzoatase appear to be non-fluorescent with blue-green cytoplasm and cell surfaces. Those tumour cells which possess uninhibited guanidinobenzoatase were located at the advancing edge of the tumour mass or were detected as small groups of individual tumour cells outside the main tumour mass. This paper is concerned with the inhibition of the guanidinobenzoatase on these cells at the advancing edge of the tumour mass, since these can be more easily located than single cells in sequential sections. The role of host tissue protein inhibitors in the control of cell migration will be discussed.
Summary A fluorescent probe has been employed to study the status of a tumour associated protease, guanidinobenzoatase, in frozen sections of human tumours obtained from the head and neck regions. The results indicate that in vivo a naturally occurring inhibitor of guanidinobenzoatase effectively controls the activity of this enzyme on the majority of cells in a tumour mass. This inhibitor can be artificially displaced by formaldehyde treatment of the frozen sections and this treatment reveals the extent of latent enzyme in the section. In the frozen sections it was noticed that at the advancing edges of the tumour mass, the tumour cells possessed uninhibited guanidinobenzoatase, an enzyme known to degrade the link peptide between cells and fibronectin. It was shown that a synthetic inhibitor of guanidinobenzoatase selectively inhibited the guanidinobenzoatase of the tumour cells at the advancing edge of the tumour mass. It is suggested that the guanidinobenzoatase on cells at the leading edge of the tumour mass plays an important role in the invasion of adjacent host tissue. This synthetic inhibitor of guanidinobenzoatase has no inhibitory action on other trypsin-like enzymes and might therefore be of value in limiting the growth of the tumour mass in vivo.
Guanidinobenzoatase is a trypsin-like protease associated with tumour cells (Steven et al., 1985) which may be assayed in solution by the cleavage of methylumbelliferone from the fluorogenic substrate 4-methylumbelliferyl-p-guanidinobenzoate (Steven & Al-Ahmad, 1983 ). This protease has been shown to cleave the tetrapeptide GlyArgGlyAsp which is thought to link cell surfaces to fibronectin (Pierschbacher & Ruoslahti, 1984) . Guanidinobenzoatase is competitively inhibited by 9-aminoacridine (Steven et al., 1985) , and this observation was used to locate tumour cells containing guanidinobenzoatase by fluorescent microscopy of formaldehyde fixed wax embedded sections. It was later established that most host tissues contained extractable proteins which were non-competitive inhibitors of guanidinobenzoatase in solution (Steven et al., 1988a) . These protein inhibitors prevented the binding of 9-aminoacridine to the protease of most tumour cells in fresh frozen sections (Steven et al., 1988b) , whilst some tumour cells possessed uninhibited enzyme in these frozen sections. In the present paper we have studied those tumour cells in frozen sections which possess uninhibited guanidinobenzoatase. When treated with 9-aminoacridine and examined by fluorescent microscopy these uninhibited cells exhibit cytoplasmic and cell surface yellow fluorescence; whilst other morphologically similar tumour cells with fully inhibited guanidinobenzoatase appear to be non-fluorescent with blue-green cytoplasm and cell surfaces. Those tumour cells which possess uninhibited guanidinobenzoatase were located at the advancing edge of the tumour mass or were detected as small groups of individual tumour cells outside the main tumour mass. This paper is concerned with the inhibition of the guanidinobenzoatase on these cells at the advancing edge of the tumour mass, since these can be more easily located than single cells in sequential sections. The role of host tissue protein inhibitors in the control of cell migration will be discussed.
BZAR [bis-(N-benzyloxycarbonyl-L-argininamido)-Rhodamine] was first described by Leytus et al. (1983) . BZAR inhibits guanidinobenzoatase in solution and on the surface of tumour cells (Steven et al., 1988) , but is cleaved by other trypsin-like enzymes (Leytus et al., 1983) . As both BZAR and 9-aminoacridine bind to the active centre of guanidinobenzoatase we used these inhibitors, one after the other, on region were kindly provided by the Pathology Department of the Justus-Liebig University, Giessen, West Germany. In all, over 500 frozen sections were provided from 55 subjects; these sections contained normal tissue as well as tumour cells, and the fluorescent examination was carried out in total ignorance of the pathological analysis previously carried out by conventional staining with haematoxylineosin. In this study the fluorescent analyses were carried out by F.S.S. (with no training in histology or pathology) so that analysis was based purely on the fluorescent appearance of the stained sections. Frozen sections from each tissue were mounted on 3" x 1" glass microscope slides at 22°C and subjected to four different protocols:
1. Slides were fixed in 10% formaldehyde in isotonic saline (formalin) for 2 h prior to conventional haematoxylin and eosin staining. These slides were examined by a pathologist and the results later compared with the information obtained from fluorescent staining. 2. Frozen sections were fixed in formalin for 18 h and stained with 9-aminoacridine (10-3 M) for 2 min followed by washing in isotonic saline for either 6 min (Steven et al., 1985) or for 1 min. Although the same type of staining was observed with 6 min or 1 min wash, the intensity of staining was greater after 1 min due to less solvent extraction of the bound probe. The 1 min procedure was essential for the colour photography of fresh frozen sections (see (3) below) and therefore we photographed sections after the 1 min wash on all occasions, so that valid comparisons could be made.
3. Fresh frozen sections were stained for 2 min with 9-aminoacridine (10-3 M) and washed for 1 min. These sections had never been exposed to formalin. Figure 3 in which all the cell-bound enzyme is inhibited and Figure 2 in which all the cell bound-enzyme is exposed for binding 9-aminoacridine by prior removal of inhibitors with formaldehyde. Steven et al., 1988) . BZAR was found to be a non-competitive irreversible inhibitor of guanidinobenzoatase in this chemical study although it was shown to be a good substrate of trypsin-like enzymes (Leytus et al., 1983) . Treatment of frozen sections with 10-6M BZAR resulted in the binding of BZAR to tumour cells with active guanidinobenzoatase, this bound BZAR could be directly observed by fluorescent microscopy employing appropriate wavelengths for rhodamine (data not presented here). Treatment of frozen sections with BZAR (106 M) dissolved in isotonic saline, followed by 9-aminoacridine staining completely abolished the ability of the tumour cells to bind the fluorescent probe. The appearance of the cells was similar to that shown in Figure 3 . Clearly the BZAR inhibited cell-bound guanidinobenzoatase. If the BZAR treated sections were then treated with formaldehyde and restained, those cells within the tumour mass on which the enzyme had been protected by the inhibitor were now capable of binding the 9-aminoacridine (data similar to Figure 7 ). From the data presented above it is clear that li. BZAR did not displace any inhibitor from guanidinobenzoatase but merely reacted with the uninhibited enzyme on 'active' cells at the edge of the tumour mass. We have previously shown that 9-aminoacridine is also an inhibitor of the free and cell-bound guanidinobenzoatase (Steven et al., 1985) . We considered the effect of BZAR on tumour cells previously treated with 9-aminoacridine, since both these molecules are attracted to the same active centre. Pretreatment of frozen sections with 9-aminoacridine, followed by BZAR then followed by a second 9-aminoacridine staining resulted in the same staining of the tumour cells at the advancing edge of the tumour mass (data similar to Figures  3-6) . The BZAR does not displace stacked 9-aminoacridine already in the active centre but pretreatment with BZAR prevents 9-aminoacridine being bound. Clearly both BZAR and 9-aminoacridine have an affinity for the same locus, in this case, the active centre of uninhibited cell-bound guanidinobenzoatase.
In the present situation we have one enzyme (the protease) and three classes of inhibitor, (a) the host tissue protein inhibitor, (b) our fluorescent probe 9-aminoacridine, and (c) the synthetic arginine derivative, BZAR. The fluorescence of bound 9-aminoacridine allows us to follow the enzymic activity of cells in frozen sections in the presence of the two other inhibitors and decide how these two inhibitors have reacted with the enzyme; either alone or in competition with each other. If guanidinobenzoatase is indeed significant for tumour cell advance, then BZAR also 4 may have significance as an agent for the possible control of tumour cell advance. One advantage of BZAR is that this compound is unlikely to inhibit other trypsin-like enzymes since these are capable of degrading BZAR (Leytus et al., 1983) . The low molecular weight of BZAR (638) and high solubility in aqueous media would ensure that this compound would have easy access to guanidinobenzoatase on the surface of tumour of cells in vivo. For the same reasons both BZAR and 9-aminoacridine (molecular weight 230) have no difficulty in diffusing through frozen sections and even resin embedded sections . These qualities make low molecular weight probes superior to fluorescent antibodies in this type of work. This study was supported by the Imperial Cancer Research Fund.
